In this video interview, Sharon Chan, vice-president, Johnson & Johnson Innovation – JLABS Asia Pacific, shares her views on what South Korea’s strengths are as a biotech and medtech R&D hub, JLABS's plans in the country and what role it wants for its local activities domestically and beyond.

More legal action in India that has the Bolar exception provision at its crux with Roche, in this instance warding off a local drug maker in the Evrysdi patent infringement case.

The sun shines over a sector with multi-blockbuster products in their prime. But clouds are looming, and highly innovative products that cannot replace the sales shortfalls could lead to a re-rating of the sector’s growth prospects.

The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.